Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA2 | Q15349 | 17/20 | 0.69 |
| ▸ | RPS6KA3 | P51812 | 14/20 | 0.69 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12598722 | 0.94 | RPS6KA2 (0.79) | RPS6KA2RPS6KA3MAPKAPK2 | |
| SCHEMBL16102504 | 0.88 | RPS6KA2 (0.70) | RPS6KA2RPS6KA3MAPKAPK2 | |
| SCHEMBL16101341 | 0.86 | RPS6KA2 (0.67) | RPS6KA2RPS6KA3MAPKAPK2 | |
| SCHEMBL3084607 | 0.85 | RPS6KA2 (0.88) | RPS6KA2RPS6KA3MAPKAPK2 | |
| SCHEMBL16123379 | 0.82 | RPS6KA2 (0.65) | RPS6KA2RPS6KA3MAPKAPK2 | |
| SCHEMBL12598726 | 0.82 | RPS6KA2 (1.00) | RPS6KA2RPS6KA3MAPKAPK2 | |
| SCHEMBL12598725 | 0.82 | RPS6KA2 (1.00) | RPS6KA2RPS6KA3MAPKAPK2 | |
| SCHEMBL1980558 | 0.81 | RPS6KA2 (0.84) | RPS6KA2RPS6KA3 | |
| SCHEMBL16101240 | 0.80 | RPS6KA2 (0.76) | RPS6KA2RPS6KA3MAPKAPK2 | |
| SCHEMBL1981604 | 0.80 | RPS6KA2 (1.00) | RPS6KA2RPS6KA3MAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190135835-A1 | MK2 INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-05-09 | — | — | US | disclosed |
| US-20190135835-A1 | MK2 INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-05-09 | — | — | US | disclosed |
| US-10138256-B2 | MK2 inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2018-11-27 | — | — | US | disclosed |
| EP-2968339-A1 | MK2 INHIBITORS AND USES THEREOF | Celgene Avilomics Research, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150376208-A1 | MK2 INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-12-31 | — | — | US | disclosed |
| US-20150376208-A1 | MK2 INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-12-31 | — | — | US | disclosed |
| WO-2014149164-A1 | MK2 INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014149164-A1 | MK2 INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376208-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, DUSP2, MKNK1 | RPS6KA2 11/4885RPS6KA3 75/4885MAPKAPK2 7/4885 |
| US-10138256-B2 | MK2 inhibitors and uses thereof | MKNK2, DUSP2, MKNK1 | RPS6KA2 11/4885RPS6KA3 75/4885MAPKAPK2 7/4885 |
| US-20190135835-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, DUSP2, MKNK1 | RPS6KA2 11/4885RPS6KA3 75/4885MAPKAPK2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.